Keros Therapeutics, Inc.
Company Stats
- Market Cap
- $226.0M
- as of Sep 30, 2026
- Shares Outstanding
- 19.8M
- Free Float
- 70.5%
Income Statement
- Revenue
- $244.1M
- Operating Income
- $67.6M
- Net Income
- $87.0M
- EBITDA
- $69.1M
- FCF Margin, 3Y Avg
- -29543.3%
- FCF Margin, Worst Year
- -84087.4%
Cash Flow
- Free Cash Flow
- $106.0M
- FCF Yield
- 46.9%
- Owner FCF Yield
- 34.2%
Balance Sheet
- Cash & Equivalents
- $287.4M
Returns & Capital
- Share Repurchases
- $375.0M
- SBC, 3Y Avg
- $30.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $244.1M | $106.0M | 43.4% |
| FY2024 | $3.5M | -$162.8M | -4585.9% |
| FY2023 | $151,000 | -$127.0M | -84087.4% |
| FY2022 | $0 | -$71.3M | — |
| FY2021 | $20.1M | -$63.2M | -314.3% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 3, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back